The FDA’s Office of Prescription Drug Promotion (OPDP) sent Untitled Letters to two drug manufacturers Oct. 31 alleging that direct-to-consumer (DTC) materials made false or misleading claims. “OPDP is sending an end of year message that it’s back in the enforcement business,” Wayne Pines, senior director at APCO Worldwide and editor-in-chief of Thompson Information Services’... Read More